LivingGLP1
Study S001417

Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial

ClinicalTrials.gov record

Registration

Registration
NCT02545738
Acronym
LIRALBU
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
32
Start
2015-04
Primary completion
2016-05
Lead sponsor
Steno Diabetes Center Copenhagen
Conditions
Diabetic Kidney Disease
Interventions
DRUG:Liraglutide; DRUG:placebo
Results posted
FALSE
Secondary identifiers
NIH:2014

Registered primary outcomes

  • Change in albuminuria [24 weeks]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010237Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
Natale P, The Cochrane database of systematic reviews
2025Systematic reviewPMID 39963952DOIcites ClinicalTrials.gov:NCT02545738; registry reference DERIVED:39963952
R0048817Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials
Wretlind, Asger, Figshare
2024Randomized trialDOIcites ClinicalTrials.gov:NCT02545738
R0007317Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
Wretlind A, Lipids in health and disease
2023Randomized trialPMID 37752566DOIcites ClinicalTrials.gov:NCT02545738; registry reference DERIVED:37752566
R0023234The effect of liraglutide on renal function: A randomized clinical trial.
von Scholten BJ, Diabetes, obesity & metabolism
2017Randomized trialPMID 27753201DOIcites ClinicalTrials.gov:NCT02545738; registry reference DERIVED:27753201